⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1429574 | 0.72 | — | — | |
| SCHEMBL1039276 | 0.70 | — | — | |
| SCHEMBL1040304 | 0.70 | — | — | |
| SCHEMBL728388 | 0.70 | — | — | |
| SCHEMBL1845918 | 0.68 | — | — | |
| SCHEMBL1037815 | 0.67 | — | — | |
| SCHEMBL1039964 | 0.67 | — | — | |
| SCHEMBL726530 | 0.67 | — | — | |
| SCHEMBL18474798 | 0.67 | — | — | |
| SCHEMBL16860630 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3287133-A1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | Tricida Inc. (US) | 2018-02-28 | — | — | EP | claimed |
| EP-3003327-A1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | Tricida Inc. (US) | 2016-04-13 | — | — | EP | claimed |
| WO-2014197725-A1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | TRICIDA, INC. (US) | 2014-12-11 | — | — | WO | claimed |
| EP-2016114-A2 | AMINE CONDENSATION POLYMERS AS PHOSPHATE SEQUESTRANTS | Genzyme Corporation (US) | 2009-01-21 | — | — | EP | claimed |
| WO-2007130463-A2 | AMINE CONDENSATION POLYMERS AS PHOSPHATE SEQUESTRANTS | GENZYME CORPORATION (US) | 2007-11-15 | — | — | WO | claimed |
| EP-0231622-A2 | Inhibition of the 5-lipoxygenase pathway | SMITHKLINE BEECHAM CORPORATION (US) | 1987-08-12 | — | — | EP | claimed |
| EP-3812761-B1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | RENOSIS INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-11738041-B2 | Proton-binding polymers for oral administration | RENOSIS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20220339186-A1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | RENIBUS THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| US-11197887-B2 | Proton-binding polymers for oral administration | TRICIDA, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| EP-3831395-A1 | COMPOSITIONS FOR TREATING ACID-BASE DISORDERS | Tricida Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3812761-A1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | Tricida Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-3718551-A1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | Tricida Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-2419427-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS FGFR KINASE INHIBITORS FOR THERAPEUTIC USE | Astex Therapeutics Ltd. (GB) | 2012-02-22 | — | — | EP | disclosed |
| EP-2406236-A1 | RHO KINASE INHIBITORS | Surface Logix, Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010119284-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS FGFR KINASE INHIBITORS FOR THERAPEUTIC USE | ASTEX THERAPEUTICS LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010104851-A1 | RHO KINASE INHIBITORS | SURFACE LOGIX, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| EP-2170848-A1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | AstraZeneca AB (SE) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009001132-A1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| EP-1202975-B1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORP (US) | 2005-04-06 | — | — | EP | disclosed |